Experienced professionals

Bernd Brust
Bernd BrustExecutive Chairman
As Executive Chairman of the Board of Antylia Scientific, Bernd leads with a persistent drive toward customer-driven organic and inorganic innovation leading to sustainable and profitable growth.

Bernd served as Chairman and CEO of Antylia Scientific from 2014 through December 2021. Before joining Antylia Scientific, Bernd served as President and CEO of Qualicaps, a provider of capsule manufacturing and processing equipment for pharmaceutical companies, which sold to Mitsubishi Chemical Holdings in 2013.

Prior to Qualicaps, he was Chief Commercial Operations Officer at Life Technologies Corporation, where he was responsible for its $3.5 billion global business. Bernd held prior leadership roles with Invitrogen Corporation (a predecessor of Life Technologies) and with GE Medical Systems.

 Jonathan Salkin
Jonathan SalkinCEO
As CEO of Antylia Scientific, Jon is focused on expanding our product portfolio to include more innovative scientific tools enabling our customers to discover and manufacture new therapeutics, vaccines & diagnostics. Beyond his company-wide leadership responsibilities, Jon oversees strategic planning initiatives for Antylia Scientific (including mergers and acquisitions).

Prior to joining Antylia Scientific in November 2015, Jon co-founded and served as the Executive Vice President of Devicor Medical Products, a GTCR-portfolio company sold to the Danaher Corporation in November 2014. Prior to Devicor, Jon was a Managing Director in the Healthcare group at the Royal Bank of Scotland plc.

Earlier in his career, Jon had numerous roles in Corporate Development and M&A with Cardinal Health, Dresdner Kleinwort Wasserstein (formerly Wasserstein Perella) and Deutsche Bank (formerly BT Wolfensohn).

Constantine (Dean) Mihas
Constantine (Dean) Mihas
Dean joined GTCR in 2001 and is currently a Managing Director of the firm. Prior to joining GTCR, Dean was CEO and co-founder of Delray Farms, LLC, a specialty food retailer. Prior to Delray Farms, Dean was with McKinsey & Company. Dean holds an MBA with distinction from the Harvard Business School and a BS with high distinction in finance and economics from the University of Illinois, Chicago.

Dean is head of the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices. In addition to serving as a Director of Antylia Scientific, he is currently a Director of Albany Molecular, Cebatech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Riverchase Dermatology, Regatta Medical, Rx30, Sotera, TerSera and XIFIN. Dean was previously a Director of past GTCR investments, including Actient Pharmaceuticals, ATI Physical Therapy, Convergex, Cord Blood Registry, Crealta Pharmaceuticals, Curo Health Services, Dash, Devicor Medical Products, GreatCall, Ovation Pharmaceuticals, Managed Healthcare Associates and Polypore.

Dean’s interest in the community is evident by his strong support of WBEZ Chicago Public Media, a non-commercial, public radio station financed primarily by listener contributions, where he serves as a board member and chair of the finance committee.

Sean Cunningham
Sean Cunningham
Sean joined GTCR in 2001 and is currently a Managing Director of the firm. He was previously a Consultant with The Boston Consulting Group. Sean holds an MBA from the Wharton School at the University of Pennsylvania as well as AB and BE degrees in engineering sciences from Dartmouth College.

In addition to serving as Director of Antylia Scientific, Sean currently is a Director of Albany Molecular Research, Ceba-Tech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Regatta, Riverchase Dermatology, Sotera and Transaction Data Systems. He was instrumental in GTCR’s past investments in Cord Blood Registry, Devicor Medical Products, Graceway Pharmaceuticals and Ovation Pharmaceuticals.

Ben Daverman
Ben Daverman
Ben joined GTCR in 2008 and is currently a Managing Director of the firm. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in history magna cum laude from Colgate University. Ben also holds a master’s degree in biotechnology from the School of Applied Sciences & Engineering at the University of Pennsylvania.

In addition to serving as a Director of Antylia Scientific, he is currently a Director of Albany Molecular Research, Corza Health, Maravai LifeSciences, TerSera and XIFIN.

Ben was previously a Director of past GTCR investments such as Actient Pharmaceuticals and Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics. In addition, Ben was involved in transactions with past GTCR investments ATI Physical Therapy and Graceway Pharmaceuticals.

Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.

Syed Jafry
Syed Jafry
Syed Jafry joined the Board of Antylia Scientific in 2022. Mr. Jafry is a veteran of the healthcare industry and most recently served as SVP & President, Asia Pacific, EMEA & Emerging Markets at Thermo Fisher Scientific. Under Mr. Jafry’s leadership, these markets achieved above plan growth with an exceptional double digit revenue growth CAGR in Asia Pacific and China over a decade. Mr. Jafry’s career with Thermo Fisher began in 2005 and over those 17 years, Mr. Jafry served in numerous capacities including General Manager of Air Quality Instruments, President of Thermo Fisher China, President of Thermo Fisher Global Environmental Instruments, and SVP of Global Customer Excellence.

Prior to Thermo Fisher, Mr. Jafry held leadership positions in various General Electric (GE) businesses, including plastics, energy and infrastructure, and was based in various locations across the US, the Netherlands and Switzerland. In addition to serving as a Director of Antylia Scientific, Mr. Jafry also serves on the Board of Directors of Zimmer Biomet, a global leader in orthopedics.

Robert Kirby
Robert Kirby
Robert Kirby joined the Board of Antylia Scientific in March 2017. Mr. Kirby is an Operating Partner with Golden Gate Capital and currently serves as CEO of Atrium Windows, a Golden Gate Capital portfolio company. Mr. Kirby was previously CEO of Vi-Jon, a leading private label manufacturer in the personal care market. Prior to this Mr. Kirby was CEO of Accellent, a leading contract manufacturer in the medical device market. Earlier in Mr. Kirby’s career, he was a GM and led R&D, Global Manufacturing & Supply Chain at large cap companies, including Johnson & Johnson, Kimberly Clark and Fort James. Mr. Kirby has broad based experience in Consumer Personal Care, OTC and Medical Devices. During his 30 year career he has led large scale and complex integrations of acquisitions, implemented lean processes and driven rapid, positive change.
Greg Lucier
Greg Lucier
Greg Lucier serves as the CEO of Corza Health and founded Corza Health in partnership with GTCR to combine his 30+ years of life sciences leadership with GTCR’s unrivaled track record of creating unique, value-generating private equity opportunities.

Greg most recently served as CEO at NuVasive, a world leader in minimally invasive spine surgery technology. Prior to that, he was CEO at Life Technologies—formerly Invitrogen—which he grew into a global life sciences powerhouse that was acquired by Thermo Fisher Scientific. He spent the first part of his career with the General Electric Company in a variety of executive roles.

In addition to serving as a Director of Antylia Scientific, Lucier remains the Chairman of Nuvasive, and serves on several public and private company boards, including Catalent, a leader in advanced pharmaceutical manufacturing services, Dentsply Sirona, a global provider of professional dental products and technologies, and Epic Sciences, a venture-backed company revolutionizing the use of cellular imaging to change cancer therapy.

Dennis Pope
Dennis Pope
Dennis Pope joined the Board of Antylia Scientific in September 2014. Mr. Pope brings a truly unique background to the Board as he has served in leadership capacities for both Antylia Scientific and Environmental Express. Mr. Pope served as Chief Executive Officer at Environmental Express from 2006 to 2013. Prior to his role at EE, he served as President at Kendro Laboratory Products, Division of SPX Corporation from 2000 to 2005 and he also served at Executive VP and COO at Antylia Scientific from 1996 to 2000.